Physician profile
Sunya Ashraf
NPI 1437579554
$555.50
in general payments reported to CMS, 2019-2025
9 companies · $53.18 in 2025
The $53.18 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $201 · 2021: $12.70 · 2022: $29.01 · 2023: $36.71 · 2024: $78.43 · 2025: $53.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.11 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $93.19 | 2022-2024 | Zerbaxa, Recarbrio, Dificid |
| Astrazeneca Pharmaceuticals Lp | $53.18 | 2025 | Fasenra, Airsupra |
| Shionogi INC | $36.71 | 2023 | Fetroja |
| Mallinckrodt Hospital Products INC. | $31.40 | 2020 | |
| Advanced Respiratory, INC | $26.41 | 2020 | |
| Glaxosmithkline, LLC. | $24.98 | 2020 | |
| Olympus America INC. | $21.27 | 2019 | |
| Chiesi USA, INC. | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunya Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.